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Background and purpose: Cardiovascular risk factors can increase the risk of
multiple sclerosis (MS) and modify its course. However, such factors possibly
interact, determining a global cardiovascular risk. Our aim was to compare
the global cardiovascular risk of subjects with and without MS with the sim-
pliﬁed 10-year Framingham General Cardiovascular Disease Risk Score (FR)
and to evaluate its importance on MS-related outcomes.
Methods: Age, gender, smoking status, body mass index, systolic blood pres-
sure, type II diabetes and use of antihypertensive medications were recorded
in subjects with and without MS to estimate the FR, an individualized per-
centage risk score estimating the 10-year likelihood of cardiovascular events.
Results: In total, 265 MS subjects were identiﬁed with 530 matched controls.
A t test showed similar FR in cases and controls (P = 0.212). Secondary pro-
gressive MS presented signiﬁcantly higher FR compared to relapsingremit-
ting MS (P < 0.001). Linear regression analysis showed a direct relationship
between FR and Expanded Disability Status Scale (P < 0.001) and MS Sever-
ity Scale (P < 0.001).
Conclusion: The FR, evaluating the global cardiovascular health by the inter-
action amongst diﬀerent risk factors, relates to MS disability, severity and
course.
Introduction
Multiple sclerosis (MS) is a chronic disorder of the
central nervous system whose pathogenesis and clini-
cal course are inﬂuenced by the interaction of environ-
mental, genetic and autoimmune factors [1].
Intriguingly, risk factors for MS also include cardio-
vascular risk factors that can be modiﬁed, with subse-
quent possible eﬀects on MS evolution.
In particular, the prevalence of cardiovascular
disorders is slightly higher or, probably, not diﬀerent
in MS subjects, as compared to the general population
[2–6]. However, MS subjects presenting vascular com-
orbidities seem to have higher chances of ambulatory
disability [7]. Moreover, being overweight apparently
increases MS risk and MS-related morbidity [8–10].
Similarly, MS subjects are more at risk of insulin
resistance, another factor possibly increasing MS-
related disability [10]. In addition, cigarette smokers
are more at risk of MS and have worse MS clinical
and neuroradiological outcomes, with higher risk of
secondary progression and increased mortality rate
[11–15]. Finally, high sodium intake, a regulating fac-
tor of blood pressure, has been related to clinical and
radiological MS exacerbations [16].
In conclusion, there are several studies evaluating
single cardiovascular risk factors in MS and their
impact on the course of the disease [2–17]. However,
it is possible that MS outcomes are aﬀected by the
interaction of diﬀerent cardiovascular risk factors,
and studies evaluating single factors have missed this
perspective. Therefore the present study aims to evalu-
ate (i) the global cardiovascular risk in MS with the
simpliﬁed 10-year Framingham General Cardiovascu-
lar Disease Risk Score (FR), a standardized algorithm
estimating the 10-year likelihood of cardiovascular
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events [22]; (ii) diﬀerences in FR between subjects
with and without MS; (iii) possible relationships
between FR and MS-related disability, severity and
treatment choice.
Methods
Study design
This is a cross-sectional casecontrol study evaluating
the FR in subjects with and without MS and its rela-
tionships with MS clinical features. Considering that
all clinical assessments were part of clinical practice in
a university setting, speciﬁc ethical approval was not
required. All subjects signed the general informed con-
sent form, authorizing the use of observational clinical
data for research purposes. The study was performed
in accordance with good clinical practices and the
Declaration of Helsinki.
Subjects with MS
Multiple sclerosis subjects were consecutively identi-
ﬁed at the MS Centre of ‘Federico II’ University
Hospital in Naples, Italy, whilst attending their
scheduled visit in September 2014, according to clin-
ical practice. The main inclusion criterion was a
diagnosis of deﬁnite MS according to Poser or
McDonald criteria [19,20]. Subjects presenting MS-
related conditions possibly aﬀecting neurological or
cardiovascular evaluation, such as current clinical
relapse, recent disease-modifying treatment (DMT)
change (<6 months, a time usually assumed as nec-
essary for DMTs to achieve their clinical eﬃcacy)
or recent corticosteroid treatment (<1 month), were
excluded.
Trained physicians evaluated all MS subjects for
MS clinical features. Kurtzke’s Expanded Disability
Disease Score (EDSS) was adopted to evaluate cur-
rent MS-related disability [21]. In order to rate dis-
ease severity, disease duration (years since clinical
onset) was recorded and the MS Severity Scale
(MSSS) was calculated [22]. Current DMT was
recorded and MS subjects were categorized according
to the treatment (interferon, natalizumab or ﬁngoli-
mod) or as not undergoing any DMT. DMTs were
prescribed according to current European Medicines
Agency indications [23]. MS subjects were categorized
according to the clinical course in relapsingremit-
ting MS (RRMS) or secondary progressive MS
(SPMS) [24]. For RRMS, the occurrence of clinical
relapse during the previous 12 months was recorded.
Finally, all MS subjects were investigated for FR
items [18].
Subjects without MS
Controls were identiﬁed amongst subjects visiting the
same hospital within the same period (September
2014) for their scheduled visit at the Occupational
Medicine Unit, in accordance with Italian regulations
for preventive purposes. All subjects without MS
underwent a detailed medical history and examina-
tion; comorbidities and current medications were
recorded. FR was subsequently calculated [18].
Framingham risk score assessment
Cardiovascular risk factors were directly assessed to
calculate the FR in subjects with and without MS. In
particular, from age, gender, smoking status, body
mass index (BMI), systolic blood pressure, type II dia-
betes and use of antihypertensive medications it is
possible to calculate the FR based on non-laboratory
predictors, an individualized percentage risk score esti-
mating the 10-year likelihood of cardiovascular events
(coronary, cerebrovascular, peripheral arterial disease
and heart failure) [18].
The FR single item evaluation was performed as
previously suggested [18,25]. In particular, smoking
habits were recorded and persons who smoked regu-
larly during the previous 12 months were classiﬁed as
smokers. Height and weight were measured with stan-
dardized hospital clinical methods, and BMI was cal-
culated. Two blood pressure determinations were
made after the participant had been sitting at least
5 min, and the average was used for analyses. Type II
diabetes was considered present if the participant was
under treatment with insulin or oral hypoglycaemic
agents or if fasting blood glucose exceeded 126 mg/dl
in previous blood examinations (all subjects per-
formed at least two diﬀerent blood tests in the previ-
ous 12 months, according to clinical practice) [18].
Subjects presenting serious concomitant illnesses
(i.e. cancer or hepatitis) or treatments (i.e. chemother-
apy) possibly interfering with cardiovascular risk were
excluded.
Considering that the FR is composed of both modi-
ﬁable (smoking, BMI, systolic blood pressure, type II
diabetes and use of antihypertensive medications) and
not-modiﬁable (age, gender) risk factors, statistical
analysis has been adjusted for age and gender in order
to better understand the impact of modiﬁable cardio-
vascular risk factors on MS.
Sample size estimation
Considering the main outcome of the present study
(diﬀerence in FR between subjects with and without
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MS), a sample of 105 subjects for each group was
considered necessary to obtain an acceptable estimate
(a = 0.05; power = 0.8; eﬀect size d = 0.5).
Statistical analysis
In the ﬁrst part of the study, a cross-sectional
casecontrol evaluation was performed to assess dif-
ferences in the FR between cases and controls. MS
subjects were individually matched to subjects without
MS according to age (within 2 years) and gender, with
a case:control matching ratio of 1:2. Diﬀerences in
demographics and in cardiovascular risk factors (FR,
smoking status, BMI, systolic blood pressure, use of
antihypertensive drugs, diabetes) between cases and
controls were explored with the v2 test, McNemar’s
test or t test, as appropriate. Subsequently, the model
considering the FR was included in an analysis of var-
iance (ANOVA) adjusted for age, gender and then FR
items (smoking status, BMI, systolic blood pressure,
use of antihypertensive drugs, diabetes).
In the second part of the present study, relation-
ships between FR and MS clinical features were eval-
uated. The analysis of the FR was performed with
linear regression analysis (EDSS, MSSS) or ANOVA
(current DMT, clinical course, occurrence of a
relapse), as appropriate. The model was adjusted for
age, gender and then FR components (smoking status,
BMI, systolic blood pressure, use of antihypertensive
drugs, diabetes).
Stata 12.0 and Microsoft Excel were used for data
processing and analysis. Each of the analyses was
tested for normal distribution of residuals by using
both statistical and graphical methods. Results were
considered statistically signiﬁcant for P < 0.05.
Results
In the ﬁrst part of our study, 265 MS subjects were
included and 530 controls were subsequently matched
for age and gender. Cases and controls were similar
for age, gender, BMI and smoking status (P = 0.275,
P = 0.999, P = 0.159 and P = 0.169, respectively)
(Table 1). Controls presented higher systolic blood
pressure (P = 0.010) and use of antihypertensive drugs
(P < 0.001) compared to MS subjects (Table 1). MS
subjects presented higher prevalence of diabetes com-
pared to controls (P < 0.001) (Table 1). The FR was
not diﬀerent between cases and controls (P = 0.212)
(Table 1). The latter result was conﬁrmed with ANOVA
adjusted for age and gender (P = 0.486; adjusted
R2 = 0.618) and for FR items (P = 0.476; adjusted
R2 = 0.812), and in particular was inﬂuenced by age
(P < 0.001), gender (P < 0.001), smoking status
(P < 0.001), BMI (P < 0.001), systolic blood pressure
(P < 0.001), use of antihypertensive drugs (P < 0.001)
and diabetes (P < 0.001).
In the second part of our study, only MS subjects
were evaluated. Linear regression analysis showed a
direct relationship between FR and EDSS before
(P < 0.001) but not after correction for age, gender
(P = 0.285) and FR items (P = 0.217) (Table 2). Fur-
thermore, linear regression analysis showed a direct
relationship between FR and MSSS before
(P < 0.001) (Fig. 1) and after correction for age, gen-
der (P = 0.003) and FR items (P = 0.022) (Table 2).
DMTs performed in the population were interferon
(n = 148; FR = 6.7  6.1), natalizumab (n = 63; FR =
4.6  5.3), ﬁngolimod (n = 36; FR=6.3  6.4) or no
current treatment (n = 18; FR = 8.7  9.9). None of
the subjects was treated with glatiramer acetate. ANO-
VA did not show diﬀerences in FR amongst subjects
undergoing diﬀerent DMTs before (P = 0.057) and
after correction for age, gender (P = 0.277) and FR
items (P = 0.165) (Table 2).
The t test showed signiﬁcantly higher FR in SPMS
compared to RRMS (P < 0.001) (Fig. 2; Table 2).
ANOVA analysis conﬁrmed the latter result after adjust-
ing for age, gender (P = 0.001) and FR items
(P = 0.029) (Table 2).
When evaluating RRMS, 54 subjects (out of 215
RRMS) experienced a clinical relapse during the pre-
vious 12 months. FR showed no diﬀerence between
subjects presenting a clinical relapse during the previ-
ous 12 months (4.9  5.5) and those not (4.9  5.7)
on t test (P = 0.434) and on ANOVA adjusted for age,
gender (P = 0.160) and FR items (P = 0.644)
(Table 2).
Discussion
This is the ﬁrst study that not only separately consid-
ered cardiovascular risk factors but also evaluated
their biological interactions by the FR, assessing the
global cardiovascular health in MS subjects.
Considering our primary objective, subjects with
and without MS presented only slight diﬀerences in
systolic blood pressure, use of antihypertensive drugs
and diabetes prevalence, whereas they did not diﬀer in
the predicted risk of cardiovascular events within
10 years. Interestingly, previous studies investigating
the prevalence of cardiovascular events in MS
[2,26,27] suggested an increased frequency of ischae-
mic stroke possibly biased by magnetic resonance
imaging surveillance [2] or mediated, at least in part,
by widespread cerebral hypoperfusion due to impaired
neuroaxonal metabolism [6]. In addition, an increased
frequency of venous thromboembolic disorders has
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been found, suggesting immobility as a possible factor
[2]. However, such cardiovascular events might have
been related also to an increased cardiovascular risk
that, unfortunately, these studies did not investigate.
In the second part of the present study, MS subjects
were analysed for clinical correlates of the FR. In par-
ticular, both EDSS and MSSS were evaluated.
Although they ultimately refer to MS-related disabil-
ity, the MSSS accounts for both disease duration and
disability and is a reliable marker of severity in MS
evolution [22]. In more detail, cardiovascular risk fac-
tors and, in particular, modiﬁable ones appeared to
aﬀect the speed in disability accrual (evaluated by the
MSSS) more than the disability itself. In addition, this
association was not inﬂuenced by single cardiovascu-
lar factors but by their interaction, evaluated with the
FR. Moreover, the global predicted cardiovascular
risk related to a secondary progressive course, and
this association was only in part inﬂuenced by single
cardiovascular risk factors. Therefore the biological
interaction of diﬀerent cardiovascular risk factors
determining a global cardiovascular risk (FR) is
strongly associated with increased MS disability and
severity and with a secondary progressive course.
Considering possible biological mechanisms, it has
been hypothesized that cardiovascular comorbidities
might increase peripheral low-grade inﬂammation,
with subsequent progressive activation of the systemic
inﬂammatory cascade, worsening demyelination and
neurodegeneration in MS [28].
Finally, some limitations need to be reported, such
as the cross-sectional design, not exploring a possible
causality. For instance, an increase in the cardiovas-
cular risk might also be related to disability-related
reduced mobility, with subsequent diﬀerences
between RRMS and SPMS. Furthermore, there is a
risk of a surveillance bias for MS subjects undergo-
ing periodic medical visits. In addition, it is possible
to calculate the FR considering lipid proﬁle instead
of BMI. Unfortunately, standardized cholesterol
measurements were not available for all subjects,
and further studies are warranted on this issue, since
an adverse lipid proﬁle has been associated with MS
evolution [28,29]. However, both FR versions are a
reliable index of the 10-year risk of cardiovascular
events [22]. Moreover, the inclusion of subjects visit-
ing our centre in a limited time (September 2014)
might have determined a selection bias with an
increased prevalence of those subjects more fre-
quently visiting our centre (i.e. natalizumab-treated
subjects). In line with this, the absence of primary
progressive MS and of subjects treated with glatir-
amer acetate must be reported, raising some general-
izability concerns on this population. However, the
present study should be considered preliminary and
further investigations are warranted to explore these
open issues.
In conclusion, the global cardiovascular risk does
not appear to be diﬀerent between subjects with and
without MS. However, the FR is related to MS dis-
ability, severity and course. Therefore, modiﬁable car-
diovascular risk factors should be investigated and
corrected with a possible eﬀect on MS-related out-
comes.
Table 1 Cardiovascular risk in MS subjects
and controls
Subjects with MS
(n = 265)
Subjects without
MS (n = 530) P value
Gender: male/female 101/164 202/328 0.999
Age, years  SD (range) 42.2  10.9 (18–65) 42.9  9.7 (20–65) 0.275
Age at onset,
years  SD (range)
29.9  8.2 (14.5–52.0) – –
Disease duration,
years  SD (range)
8.2  6.5 (0.5–29.7) – –
Smokers, n (%) 99 (37.4) 192 (36.2) 0.169
BMI, kg/m2  SD
(range)
26.3  4.5 (16.5–44.7) 26.6  4.9 (17.5–50.2) 0.159
Systolic blood pressure,
mmHg  SD (range)
118.9  13.6 (90–170) 121.6  14.6 (70–180) 0.010
Use of antihypertensive
drugs, n (%)
35 (13.2%) 42 (7.9%) <0.001
Diabetes, n (%) 5 (1.9%) 4 (0.7%) <0.001
FR, mean  SD (range) 6.5  6.3 (0.2–37.2) 6.9  7.0 (0.2-37.1) 0.212
Male 9.9  7.6 (0.5–37.2) 10.5  8.4 (1.1–37.1) 0.122
Female 4.7  4.7 (0.2–30.0) 4.8  4.7 (0.2–30.2) 0.364
MS, multiple sclerosis; BMI, body mass index; FR, simpliﬁed 10-year Framingham General
Cardiovascular Disease Risk Score.
Demographics, cardiovascular risk factors and Framingham risk score in subjects with and
without MS. Results are shown from the v2 test, McNemar’s test or t test, as appropriate.
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